Got $2,000? 2 Top Growth Stocks to Buy That Could Double Your Money.

Chewy: sales continue to grow despite its stock being down ~80% from pandemic highs; analysts forecast revenue growth of ~6% for fiscal 2025 and ~8% the following year, current trailing P/E ~52 and forward P/E ~16, and the company is expanding initiatives (Chewy Plus, pet pharmaceuticals, telehealth). Target: fiscal 2025 revenue $105B (-2% YoY) and net income $3.7B (-9% YoY), stock down >55% from 2021 peak; new CEO Michael Fiddelke plans $5B in store/remodel and operations investments, company guides to ~2% sales growth for fiscal 2026, offers $4.56 annual dividend (3.9% yield) and trades at ~14x P/E versus Walmart at 46x.

Analysis

Chewy’s push into higher-margin, recurring revenue channels (subscriptions, prescriptions, telehealth) is less a retail fad and more a structural pivot that can meaningfully lift customer LTV and gross margin if retention improves by even a few percentage points. That creates a multi-quarter runway: inventory and fulfillment complexity will increase short-term, but successful cross-sell cadence (prescriptions + autoship) converts low-frequency buyers into monthly customers, compressing CAC payback and improving FCF conversion over 12–24 months.

Target’s remediation is an operations story more than a merchandising one: store remodels plus supply-chain investments can raise sales density and reduce working-capital drag, effectively funging as a high-return “capex = margin” program if inventory turns accelerate by 4–8%. The valuation upside is therefore tied to visible, quantifiable KPI inflection (inventory days, comp sales, private-label mix) rather than headline sentiment, so the market will reward 2–4 consecutive quarters of unit-level improvement.

Second-order competitive dynamics: if Chewy captures durable prescription share, veterinary wholesalers and mid-market retailers face margin pressure and may cede pricing control or accept exclusivity terms, widening Chewy’s moat but inviting regulatory scrutiny. Near-term catalysts to watch are subscription take-rate, pharmacy margin per order, and a 2–4 quarter path to free-cash-flow breakeven; key tail risks are macro-induced cutbacks in discretionary pet spend and execution slippage on supply-chain investments.

Key Decisions for Investors

• Long CHWY (12–18 months): establish a 1.5–2.5% portfolio position via common stock or LEAP calls ~12–18 months out ~15–30% OTM to capture subscription/pharmacy monetization. Reward: asymmetric upside if retention + pharmacy margins expand (target +50–80% IRR). Risk: stop at -35% from entry or hedge with short-dated puts if quarterly retention disappoints.
• CHWY defined-risk option spread (9–12 months): buy a call spread financed by selling a further OTM call to cap cost (buy 12m 15–25% OTM / sell 12m 50–70% OTM). Use this to express catalyst-driven re-rate into next two earnings cycles; max loss = premium paid, upside capped but >2x if catalyst hits.
• Long TGT equity + covered-call overlay (12 months): buy shares for a 2–3% portfolio weight and sell 1-year OTM calls ~10–15% above spot to monetize dividend and near-term re-rating. Reward: harvest dividend yield + 15–25% upside if execution accelerates. Risk: downside of ~25–35% on execution failure; roll calls or buy protection below key moving-average support.
• Relative-value pair (6–12 months): long CHWY / short WMT equal-dollar to express pet premiumization vs mass price leader. Expected relative return +20–30% if Chewy’s LTV gains materialize; risk: defensive rotations or broad market stress that benefit WMT—cut pair if relative performance reverses by 10% within 60 days.